Heart Failure

Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.

Tirzepatide reduced the risk of severe heart failure outcomes by 38% and drove weight loss of 15.7% in adults with HFpEF and obesity, with and without T2D..

Your daily dose of the clinical news you may have missed.

Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Your daily dose of the clinical news you may have missed.

Patients with HF who received SGLT2i therapy had significant improvement in functional capacity and QOL, regardless of sex, diabetes status, or ejection fraction, report researchers.

The majority of the US adult population meets criteria for subclinical CKM syndrome indicating "an urgent need for population-wide risk reduction measures."

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

The Low EF AI is designed to detect low ejection fraction in 15 seconds during a primary care exam.

ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.

Your daily dose of the clinical news you may have missed.

The novel SGLT-2/SGLT-1 inhibitor reduced risk of stroke, MI, and demonstrates significant antiplatelet activity in post-hoc analyses of SCORED phase 3 trial.

New research highlights another benefit of COVID-19 vaccination, reported researchers.

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

Uptitration of renin-angiotensin-aldosterone system inhibitors was less successful in women with acute heart failure, and particularly those with heart failure with reduced ejection fraction.

Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.

Your daily dose of the clinical news you may have missed.

Results from a new study of Medicare beneficiaries admitted for an emergency general surgery show the odds of 30-day readmission was 67% lower for those with follow-up visit.

Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.

Your daily dose of clinical news you may have missed.

New research shows that patients with heart failure who had more steps per day and increasing steps per day experienced better health status over 12 weeks.

Your daily dose of clinical news you may have missed.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

ESC 2023: Early initiation of dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in patients hospitalized with ADHF.

ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.

A daily dose of clinical news on Patient Care you may have missed.

A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.